Conferences - Results from #9580

GU Cancers Symposium 2014 - Novel long noncoding RNA-dependent mechanisms of androgen receptor-regulated gene activation - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Unleashing the power of the immune system through combination therapy - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Dissecting the biology of the androgen receptor pathway - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study - Session Highlights January 30, 2014

Myriad's Prolaris® test significantly modifies treatment decisions for patients with prostate cancer January 29, 2014

Symposium highlights latest research advances in GU cancers January 28, 2014

GU Cancers Symposium 2014 - Premature termination of genitourinary cancer clinical trials - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Impact of angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII) - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Enzalutamide decreases risk of death and delays progression in phase III trial of men with metastatic prostate cancer - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase 3 PREVAIL study - Abstract January 25, 2014

Myriad Genetics to present five clinical studies at 2014 ASCO GU Cancer Symposium January 23, 2014

Embargoed presscast on January 28 to feature key research advances in genitourinary cancers, embargoed press release now available January 23, 2014

SUO 2013 - Session Highlights (Best Abstract Presentation): Experience with active surveillance (AS) in patients with renal mass > 4cm: Assessment of growth kinetics and outcomes December 10, 2013

SUO 2013 - Session Highlights: Evaluation of surveillance guidelines for renal cell carcinoma following partial nephrectomy December 10, 2013

SUO 2013 - Session Highlights: Targeted magnetic resonance imaging/ultrasound fusion biopsy significantly outperforms random 12-core biopsy for prediction of total prostate cancer tumor volume December 10, 2013

SUO 2013 - Session Highlights: NEUACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer (UC): Updated analysis of product parameters, HER2 expression and safety December 9, 2013

SUO 2013 - Session Highlights: The influence of race on RCC incidence and survival December 9, 2013

SUO 2013 - Session Highlights: Comparative effectiveness research studies of robotic vs. open prostatectomy December 9, 2013

SUO 2013 - Session Highlights: Multicenter retrospective experience in the surgical management of isolated nodal recurrences post-nephrectomy in patients with renal cell carcinoma December 9, 2013

Page 480 of 522